Stock Financial Ratios, Dividends, Split History

XOMA / XOMA Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price23.02
Volume46,600.00
Market Cap ($M)598.63
Enterprise Value ($M)489.22
Book Value ($M)178.72
Book Value / Share6.90
Price / Book3.35
NCAV ($M)101.45
NCAV / Share3.92
Price / NCAV5.90
Share Statistics
Common Shares Outstanding 25,706,590
Common Stock Shares Outstanding 25,696,796
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 25,018,000
Weighted Average Number Of Diluted Shares Outstanding 25,322,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.03
Return on Equity (ROE)0.03
Balance Sheet (mrq) ($M)
Assets207.25
Liabilities28.53
Quick Ration/a
Current Ratio5.43
Income Statement (mra) ($M)
Sales Revenue Goods Net0.00
Advertising Revenue115,787,000.00
Transactions Revenue27,106,000.00
Registry Services Revenue0.00
Publishing Revenue17,663,000.00
Revenues160,556,000.00
Operating Income14.19
Net Income5.53
Earnings Per Share Diluted0.22
Earnings Per Share Basic0.22
Cash Flow Statement (mra) ($M)
Cash From Operations24.80
Cash from Investing-8.82
Cash from Financing-8.82
Identifiers and Descriptors
CUSIP98419J107
Central Index Key (CIK)1062292
Related CUSIPS
98419J907 98419J957 98419J206

Split History

Stock splits are used by XOMA Corporation to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

4 Picks From Millennials' Pet Tech & Restaurant Sectors

2018-07-13 zacks
Gone are the days when millennials were dependent on parents and unlikely to have surplus cash to invest in the stock market. This demography is currently the most diverse and educated generation of the United States and their stock purchase behavior has considerable impact on the market. Their attention and involvement are expected to increase in the years to come. (3-0)

YY Beats on Q1 Earnings & Revenues, Mobile Drives Y/Y Growth

2018-06-07 zacks
YY Inc. (YY - Free Report) delivered first-quarter 2018 earnings of $1.72 per American depositary shares (ADS), which handily beat the Zacks Consensus Estimate of $1.56. Revenues of $518 million also comfortably surpassed the Zacks Consensus Estimate of $491 million. In May 2018, YY’s subsidiary HUYA Inc. completed Initial Public Offering (IPO) of 17,250,000 ADS at a price of $12.00 per ADS. Top-line Details Net revenues surged 43. (35-0)

Zacks.com featured highlights include: Chemours, Nine Energy, Boise Cascade, Seagate and Meet Group

2018-05-31 zacks
Chicago, IL – May 31, 2018 - Stocks in this week’s article The Chemours Company (CC - Free Report) , Nine Energy Service, Inc. (NINE - Free Report) , Boise Cascade Company (BCC - Free Report) , Seagate Technology plc (STX - Free Report) and The Meet Group, Inc. (MEET - Free Report) . (53-0)

Zacks.com featured highlights include: Schweitzer-Mauduit, Insight, Baxter, Boise Cascade and Comfort Systems

2018-05-31 zacks
Chicago, IL – May 31, 2018 - Stocks in this week’s article Schweitzer-Mauduit International, Inc. (SWM - Free Report) , Insight Enterprises, Inc. (NSIT - Free Report) , Baxter International Inc. (BAX - Free Report) , Boise Cascade, L.L.C. (BCC - Free Report) and Comfort Systems USA, Inc. (FIX - Free Report) . (59-0)

Zacks.com featured highlights include: Johnson Outdoors, Harsco, Federated National, DMC and Town Sports

2018-05-31 zacks
Chicago, IL – May 31, 2018 - Stocks in this week’s article Johnson Outdoors Inc. (JOUT - Free Report) , Harsco Corp. (HSC - Free Report) , Federated National Holding Company (FNHC - Free Report) , DMC Global Inc. (BOOM - Free Report) and Town Sports International Holdings, Inc. (CLUB - Free Report) . (23-0)

CUSIP: 98419J107